This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • COVID-19
  • /
  • Elevated Calprotectin and Abnormal Myeloid Cell Su...
Journal

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Read time: 1 mins
Published:16th Sep 2020
Author: Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L et al.
Source: Cell
Availability: Free full text
Ref.:Cell. 2020 Sep 17;182(6):1401-1418.e18.
DOI:10.1016/j.cell.2020.08.002
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19


Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14LowCD16High monocytes, accumulation of HLA-DRLow classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101CXCR4+/− neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation.


Read abstract on library site Access full article